Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01350401
Recruitment Status : Active, not recruiting
First Posted : May 9, 2011
Last Update Posted : October 24, 2017
Information provided by (Responsible Party):

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : March 2018
  Estimated Study Completion Date : May 2031

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 January 11, 2018 February 6, 2018
2 March 16, 2018